为大脑健康创造时间:认识到痴呆的时间不平等 降低痴呆风险
Susanne Röhr1, Simone Reppermund2, Annabel Matison2
1Centre for Healthy Brain Ageing (CHeBA), School of Clinical Medicine, University of New South Wales Sydney, Sydney, Australia; Global Brain Health Institute (GBHI), Trinity College Dublin, Dublin, Ireland.
The lancet. Healthy longevity
|October 16, 2025
概括
时间是大脑健康的关键社会决定因素. 解决时间不平等或不公平的时间分配对于降低痴呆风险和促进大脑健康至关重要.
科学领域:
- 神经科学是一个神经科学.
- 流行病学 流行病学
- 社会学 社会学 社会学
背景情况:
- 时间是对大脑健康的未被认可的社会决定因素,其重要性与痴呆风险的教育或收入相当.
- 时间不平等,由于结构因素而造成的自由时间的不平等分配,包括休息不足,节奏中断,以及对工作/数字需求的侵犯.
- 时间贫困是时间不平等的一个关键方面,它不成比例地影响弱势群体,并且由绩效驱动的文化加剧.
研究的目的:
- 整合流行病学,神经科学和时间利用研究,强调时间不平等对大脑健康的重要性.
- 论证需要解决痴呆风险降低策略中的时间不平等.
- 倡导时间正义,认识到时间既是资源,也是老龄化和痴呆症不平等的场所.
主要方法:
- 文献综述综合了流行病学,神经科学和时间利用研究的见解.
- 时间不平等的概念分析及其与大脑健康和痴呆风险的关系.
- 确定未来的研究方向和政策影响.
主要成果:
- 采用健康行为对于预防痴呆症至关重要,需要足够的时间,时间分布不均.
- 时间不平等对大脑健康和痴呆症风险构成重大,但未被充分认识到的威胁.
- 当前的痴呆症预防策略如果不解决时间短缺的根本问题,可能就不那么有效.
结论:
- 解决时间不平等对于有效促进大脑健康和降低痴呆风险至关重要.
- 政策和研究必须承认时间是关键资源,并解决时间正义的不平等分配问题.
- 未来的研究应该集中在量化时间不平等,将时间使用与大脑健康联系起来,并评估促进公平时间获取的干预措施.
更多相关视频
相关概念视频
Dementia
515
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
The progression of dementia is generally gradual....
515
Alzheimer's Disease: Treatment
811
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
811
Alzheimer's Disease: Overview
1.6K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.6K


